Luca Potestio

University of Naples Federico II

Italy

Research Interests

Explore related searches

Professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (8)

Teresa Battista

ITALY

View details

Matteo Megna

University of Naples Federico II

ITALY

View details

simone ribero

University of Turin

ITALY

View details

Fabrizio Martora

ITALY

View details

Maddalena Napolitano

University of Naples Federico II

ITALY

View details

Angelo Ruggiero

ITALY

View details

Alessia Villani

University of Naples Federico II

ITALY

View details

Elisa Camela

University of Naples Federico II

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Luca Potestio

Research Interests

Explore related searches

Contact this professor

Articles (20)

Definition of treatment resistant psoriasis and related safety concerns

Real-world effectiveness of lebrikizumab on pruritus in moderate-to-severe atopic dermatitis: preliminary data from a single-center, real-life experience

The Use of JAK Inhibitors in Elderly Patients with Moderate-to-Severe Atopic Dermatitis: A Narrative Review of Clinical and Real-World Evidence

Guselkumab In A Subset Of Multifailure Patients With Hidradenitis Suppurativa: Real-Word Evidence from Federico II

Efficacy and tolerability of bimekizumab within patients with moderate-to-severe plaque psoriasis: learnings from real world evidence

Comment on ‘Potential role of leptin in Janus kinase 2 inhibitor-associated weight gain: a monocentric retrospective study’

Incidence, Risk Factors, and Management of Conjunctivitis in Atopic Dermatitis Patients Treated With Dupilumab or Tralokinumab: Results From a Multicenter, Observational, Retrospective Study

How the use of sonidegib beyond clinical complete response impacts tolerability in locally advanced basal cell carcinoma: a retrospective monocentric analysis

Biologics targeting IL-23 in moderate-to-severe psoriasis: lessons learned from real-world use

Allergic Contact Dermatitis From a Polyester Trouser Mimicking Atopic Dermatitis

Comment on “Permethrin-unresponsive scabies in London, United Kingdom – a wake up call”

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data

Advancing dermatology: embracing the power of artificial intelligence. Comment on ‘Artificial intelligence-assisted publishing in five prominent dermatology journals: a quantitative study of recent publications’

New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge

Biologics for the Management of Erythrodermic Psoriasis: An Updated Review

Comment on ‘Associations between hidradenitis suppurativa and dermatological conditions in adults: a national cross-sectional study’

Comment on ‘Onset of epidermolysis bullosa acquisita under therapy with ustekinumab for the treatment of Crohn disease’

Comment on 'Onset of epidermolysis bullosa acquisita under therapy with ustekinumab for the treatment of Crohn disease'

Reply to “Dalbavancin for the treatment of severe hidradenitis suppurativa”

ChatGPT and dermatology: friends or foes?

Collaborators (8)

Teresa Battista

Matteo Megna

simone ribero

Fabrizio Martora

Maddalena Napolitano

Angelo Ruggiero

Alessia Villani

Elisa Camela

Make your next move.